[go: up one dir, main page]

AR111203A1 - Inmunoconjugados - Google Patents

Inmunoconjugados

Info

Publication number
AR111203A1
AR111203A1 ARP180100818A ARP180100818A AR111203A1 AR 111203 A1 AR111203 A1 AR 111203A1 AR P180100818 A ARP180100818 A AR P180100818A AR P180100818 A ARP180100818 A AR P180100818A AR 111203 A1 AR111203 A1 AR 111203A1
Authority
AR
Argentina
Prior art keywords
amino acid
immunoconjugate
rhv
acid sequence
sequence seq
Prior art date
Application number
ARP180100818A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR111203A1 publication Critical patent/AR111203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Inmunoconjugado que comprende un polipéptido IL-2 mutante y una molécula biespecífica de unión a antígeno que se une a PD-1 y a Tim-3, en el que el polipéptido IL-2 mutante es una molécula de IL-2 humana que comprende las sustituciones de aminoácidos F42A, Y45A y L72G (numeración respecto a la secuencia de IL-2 humana SEC ID nº 22) y en la que la molécula biespecífica de unión a antígeno comprende: (i) una primera fracción de unión a antígeno que se une a PD-1 e (ii) una segunda fracción de unión a antígeno que se une a Tim-3. Reivindicación 2: Inmunoconjugado según la reivindicación 1, en el que la primera fracción de unión a antígeno comprende: (a) una región variable de cadena pesada (VH) que comprende una RHV-H1 que comprende la secuencia de aminoácidos SEC ID nº 1, una RHV-H2 que comprende la secuencia de aminoácidos SEC ID nº 2 y una RHV-H3 que comprende la secuencia de aminoácidos SEC ID nº 3 y (b) una región variable de cadena ligera (VL) que comprende una RHV-L1 que comprende la secuencia de aminoácidos SEC ID nº 4, una RHV-L2 que comprende la secuencia de aminoácidos SEC ID nº 5 y una RHV-L3 que comprende la secuencia de aminoácidos SEC ID nº 6. Reivindicación 29: Uno o más polinucleótidos aislados codificantes del inmunoconjugado según cualquiera de las reivindicaciones 1 a 28. Reivindicación 32: Método para producir un inmunoconjugado que comprende un polipéptido IL-2 mutante y una molécula biespecífica de unión a antígeno que se une a PD-1, y Tim-3, que comprende (a) cultivar la célula huésped según la reivindicación 31, bajo condiciones adecuadas para la expresión del inmunoconjugado y opcionalmente (b) recuperar el inmunoconjugado. Reivindicación 34: Composición farmacéutica que comprende el inmunoconjugado según cualquiera de las reivindicaciones 1 a 28 ó 33 y un portador farmacéuticamente aceptable. Reivindicación 40: Método de tratamiento de una enfermedad en un individuo, que comprende administrar en dicho individuo una cantidad terapéuticamente eficaz de una composición que comprende el inmunoconjugado según cualquiera de las reivindicaciones 1 a 28 ó 33 en una forma farmacéuticamente aceptable. Reivindicación 41: Método según la reivindicación 40, en el que dicha enfermedad es cáncer.
ARP180100818A 2017-04-03 2018-04-03 Inmunoconjugados AR111203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17164538 2017-04-03

Publications (1)

Publication Number Publication Date
AR111203A1 true AR111203A1 (es) 2019-06-12

Family

ID=58488893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100818A AR111203A1 (es) 2017-04-03 2018-04-03 Inmunoconjugados

Country Status (7)

Country Link
US (2) US20180326011A1 (es)
EP (1) EP3606947B1 (es)
JP (1) JP7148539B2 (es)
CN (1) CN110382525B (es)
AR (1) AR111203A1 (es)
TW (1) TWI780140B (es)
WO (1) WO2018184965A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287352B2 (en) 2015-10-02 2019-05-14 Hoffman-La Roche Inc. Bispecific antibodies specific for PD1 and TIM3
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
LT3606946T (lt) 2017-04-03 2022-10-25 F. Hoffmann-La Roche Ag Anti-pd-1 antikūno imunokonjugatai su mutantiniu il-2 arba su il-15
CN116375876A (zh) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
KR20200010354A (ko) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR102684426B1 (ko) * 2017-12-06 2024-07-11 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP7512210B2 (ja) 2018-09-21 2024-07-08 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 新規インターロイキン２およびその使用
JP7496091B2 (ja) * 2018-10-29 2024-06-06 １グローブ バイオメディカル カンパニー， リミテッド 合理的に設計された新規なタンパク質組成物
SG11202106700WA (en) * 2019-01-07 2021-07-29 Inhibrx Inc Polypeptides comprising modified il-2 polypeptides and uses thereof
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
EP3983433A4 (en) * 2019-06-14 2023-08-09 Cugene Inc. NOVEL INTERLEUKIN-2 VARIANTS FOR CANCER TREATMENT
AU2020294880B2 (en) * 2019-06-19 2024-05-02 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using Cre mRNA
CN114008082A (zh) * 2019-06-24 2022-02-01 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
WO2021161287A2 (en) 2020-02-16 2021-08-19 Aulos Bioscience, Inc Engineered anti-il-2 antibodies
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
WO2022189380A1 (en) * 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
TW202246358A (zh) * 2021-03-09 2022-12-01 瑞士商赫孚孟拉羅股份公司 Ｐｄ－１靶向ｉｌ－２變體免疫結合物及ｆａｐ／４－１ｂｂ結合分子的組合療法
US20240199714A1 (en) * 2021-04-16 2024-06-20 Orionis Biosciences, Inc. Il-2 based constructs
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
IL311643A (en) * 2021-09-22 2024-05-01 Fortvita Biologics Singapore Pte Ltd Interleukin-2 mutant and fusion protein
CN116178565A (zh) * 2021-09-24 2023-05-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
EP4433097A1 (en) * 2021-11-17 2024-09-25 F. Hoffmann-La Roche AG Compositions of protein complexes and methods of use thereof
AU2023217152A1 (en) * 2022-02-11 2024-08-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Immunoconjugate and use thereof
WO2023234743A1 (ko) * 2022-06-03 2023-12-07 (주)지아이이노베이션 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
CN117986383A (zh) * 2022-11-02 2024-05-07 北京昌平实验室 融合蛋白及其应用
JP2026501323A (ja) * 2022-12-22 2026-01-14 アナヴェオン アーゲー Ｉｌ－２融合タンパク質
EP4431525A1 (en) * 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156905B (it) 1977-04-18 1987-02-04 Hitachi Metals Ltd Articolo di ornamento atto ad essere fissato mediante un magnete permanente
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
JP2005507870A (ja) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−２突然変異体
CN100390282C (zh) 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
UA95068C2 (uk) 2005-02-07 2011-07-11 Глікарт Біотехнолоджі Аг Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
PL2066796T3 (pl) 2006-09-20 2011-11-30 Mt Biomethan Gmbh Sposób i urządzenie do separacji metanu i dwutlenku węgla z biogazu
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR20120053042A (ko) 2009-08-17 2012-05-24 로슈 글리카트 아게 표적화된 면역접합체
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
IL269687B (en) * 2011-02-10 2022-08-01 Roche Glycart Ag Interleukin-2 polypeptides
FI2691417T4 (fi) 2011-03-29 2025-01-14 Roche Glycart Ag Vasta-aineen Fc-variantteja
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
TR201808458T4 (tr) 2012-02-15 2018-07-23 Hoffmann La Roche FC-reseptör bazlı afinite kromatografisi.
HRP20191409T1 (hr) 2012-04-20 2019-11-15 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
JP6290209B2 (ja) * 2012-08-07 2018-03-07 ロシュ グリクアート アーゲー 低下した及び増加したエフェクター機能を有するように操作された２つの抗体を含む組成物。
WO2015070060A1 (en) * 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
RS59664B1 (sr) * 2014-11-06 2020-01-31 Hoffmann La Roche Anti-tim3 antitela i postupci upotrebe
US10287352B2 (en) * 2015-10-02 2019-05-14 Hoffman-La Roche Inc. Bispecific antibodies specific for PD1 and TIM3

Also Published As

Publication number Publication date
JP2020512814A (ja) 2020-04-30
CN110382525B (zh) 2023-10-20
US20180326011A1 (en) 2018-11-15
WO2018184965A1 (en) 2018-10-11
TWI780140B (zh) 2022-10-11
EP3606947B1 (en) 2022-12-21
US20230071733A1 (en) 2023-03-09
EP3606947A1 (en) 2020-02-12
JP7148539B2 (ja) 2022-10-05
CN110382525A (zh) 2019-10-25
TW201842937A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
AR111203A1 (es) Inmunoconjugados
PE20231851A1 (es) Proteinas que se unen a nkg2d, cd16 y clec12a
CL2020000452A1 (es) Anticuerpos de b7-h4 y métodos para usarlos.
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR110101A1 (es) Miembros de unión (2)
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PE20220575A1 (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR085334A1 (es) Inmunoterapia mejorada, composicion farmaceutica, kit
AR109715A1 (es) Anticuerpos anti-cd27
AR122761A1 (es) Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28
AR099625A1 (es) Anticuerpos de il-21
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
JP2017518258A5 (es)
AR128686A1 (es) MOLÉCULAS DE UNIÓN CONTRA FRa
AR115192A1 (es) Anticuerpos
AR105978A1 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas